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patients, implanted with a non-rechargeable device (Kinetra™, Soletra™, Itrel
®
2)
between 1996 and 2010. Overall, 117 implantations were performed (primo-implan-
tation and replacement). The mediane time to replacement of the non-recharge-
able devices was 2.9 years, ranging between 0.4 and 7.8 years. When extrapolated to
the cohort population, the use of the rechargeable device would have avoided a
total number of 215 hospitalizations over 9 years. The number of days of hospital-
ization avoided per patient was 10 days. The direct medical cost (device and hos-
pitalization tariffs) avoided per patient was 27 886€. CONCLUSIONS: Over 9 years,
the rechargeable DBS device allows to avoid 2 device replacements per patient.
This is associated with a 40 % reduction of the total number of days in hospital, and
43% reduction in the direct medical cost. The rechargeable neurostimulator
Activa
®
RC is adapted to patients with high energy needs like dystonia patients,
with a time to replacement of 5 years or less.
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OBJECTIVES: PRECISE study aims to assess the costs and the clinical benefits of
Spinal Cord Stimulation (SCS) (plus conventional medical management, CMM) in
the treatment of Failed Back Surgery Syndrome (FBSS) patients not adequately
responding to CMM alone. Being the study closed, we report the preliminary clin-
ical and resource consumption final results.METHODS:An observational, pre-post
data collection with a 24-months follow-up (FU) was developed in 9 Italian Hospi-
tals. Resource consumption, clinical outcomes (Pain Numerical Rating Scale - NRS,
Oswestry Disability Index - ODI) and HR-QoL data (SF-36, EQ-5D) were collected
before and after the SCS system implantation in order to be compared. RESULTS:
Fifty-five of the 72 patients implanted (out of the 80 enrolled for the SCS screening)
completed the study. Seventeen discontinued the therapy due to: consent with-
drawal (24%), loss to FU (24%), SCS-related issues (29%), non-SCS related reasons
(24%). Mean pain intensity decreased from 7.41.4 to 4.22.6 in the first 12 months,
remaining consistent through the second year of FU (4.12.5). A continuous im-
provement in function measured with ODI was appreciated: 47 (85%) patients im-
proved in the first year and 33 (60%) during the second, for a total of 41 (82%)
patients improved at 24-month FU if compared to the baseline. EQ-VAS increased
from 37 to 60 (12-months) to 63 (24-months). All SF-36 domains significantly im-
proved, and especially “Bodily Pain”, “Social Functioning”, “Role Emotional”. With
respect to the baseline, the monthly per-patient resource consumption decreased:
considering the second year of follow-up, both pain-related hospitalizations and
GP visits experienced a 70% reduction in number, diagnostic exams diminished by
the 82%. Monthly caregivers’ days off from work dropped by the 80% (from 45 to 9).
CONCLUSIONS: SCS allows a better and sustained pain control and HR-QoL im-
provement. If compared with CMM alone, SCS permits a reduction in resource
consumption and productivity losses.
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OBJECTIVES:Diagnosis of patients with dyspnea and suspected acute heart failure
(HF) using NT-proBNP testing has been studied internationally. We aimed to ana-
lyze the efficiency of NT-proBNP compared to standard clinical evaluation alone
use in Spanish Emergency Departments. METHODS: A decision-analytic model
was developed to evaluate the clinical and economic outcomes of both diagnostic
alternatives. Model’s time horizon started at patient ED visits and ended after 60
days of follow-up (taking into account differences between hospitalized and non-
hospitalized patients). Clinical parameters were mainly extracted from the PRIDE
study and were validated by expert opinion (ED and cardiology doctors). We as-
sumed that 65% of patients with dyspnea had HF based on Spanish published data.
Resource use was obtained through expert opinion and examined under a National
Healthcare System (NHS) perspective. We considered a 900 pg/ml cut-point for
NT-proBNP test (sensitivity of 90% and specificity of 85%). Our model compared
final diagnostic result with the initial diagnostic before ED discharge. A probabilis-
tic sensitivity analysis was carried out in order to handle uncertainty. RESULTS:
Diagnosis using NT-proBNP testing was correct in 91.96% of patients (59.09% true
positive cases and 32.87% true negative cases) versus 85.53% with the standard
clinical evaluation alone (50.79% of true positive cases and 34.74% of true negative
cases). Besides, NT-proBNP testing involved less costs (4,045€ versus 5,405€) mainly
due to less hospitalizations and a shorter length of stay. Robustness of results was
confirmed through a sensitivity analysis. CONCLUSIONS: NT-proBNP test is less
costly per correctly diagnosed patient than standard clinical evaluation alone in
the assessment and management of patients with dyspnea at ED rooms from Span-
ish NHS perspective.
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OBJECTIVES: Liver imaging techniques aim to correctly characterize focal lesions
and influence choices of therapeutic strategies. The objective of this study was to
compare diagnostic efficacy and direct medical costs of contrast-enhanced ultra-
sound (CEUS) to magnetic resonance imaging (MRI) or computed tomography (CT)
in the characterization of focal liver lesions in the The Netherlands. METHODS:
This prospective study enrolled 170 patients at an academic hospital in the The
Netherlands. A decision model was designed to compare two diagnostic algorithms
based on the results of the study: 1) a typical patient work-up, which included
ultrasound (US), followed by an MRI or CT examination, and 2) a new patient
work-up in which CEUS was performed after US. The perspective of the healthcare
sector in the The Netherlands was used. Clinical outcomes were ‘correctly charac-
terizedx benign and malignant liver lesions and life-years (LY). Model inputs were
taken from the hospital database, literature and publicly available sources. Time
horizon was two years. One-way and probabilistic sensitivity analyses were per-
formed to assess uncertainty in the results. RESULTS: CEUS was able to identify
benign and malignant focal liver lesions with a sensitivity of 96.9% and specificity
of 92.3%. For correct tumor subgroup characterization, sensitivity and specificity
were 86.2% and 85.6% respectively. Base-case results revealed that the CEUS strat-
egy had similar effectiveness compared to the MRI/CT strategy (incremental effects
of 0.002 LYs) and resulted in cost-savings of €452. The cost-savings for diagnostic
phase and treatment phase were €160 and €292 respectively. The results were
sensitive to specificity, sensitivity and cost of the diagnostic tests. Robustness of
the results was confirmed by probabilistic sensitivity analysis. CONCLUSIONS:
This study demonstrates that CEUS is a cost-saving alternative compared to the
traditional diagnostic procedures and should be considered as one of the ‘first
stepx options in the front-line characterization of focal liver lesions in the The
Netherlands.
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OBJECTIVES: The treatment of chronic lymphoedema (CL) is of particular health
economic interest since, due to its chronic nature and continuous need for treat-
ment, it is associated with high costs and considerable patient burden. The objec-
tive of this study was to assess the cost-effectiveness of 3M™ Coban 2™ compres-
sion system in the treatment of CL compared to Comprilan® short-stretch bandage
compression therapy. METHODS: In the UK and the United States a multi-center,
prospective, open-label study was conducted, including patients with CL of the legs
(n40) and the arms (n42). Patients were randomly assigned to the four treatment
arms (3M™ Coban 2™ compression treatment either daily, 2x/wk or 3x/wk, and
daily compression therapy with Comprilan® bandages). Cost analysis from the UK
payors’ perspective was based on material costs and personal resource utilization
for bandage changes and for manual lymphtherapy. Clinical outcomes in the cost-
effectiveness analysis was defined as mean volume reduction at the end of therapy
(19 days). RESULTS: On average, 3 weeks treatment for a patient with lymphoe-
dema added to 1,297.96 € for the health service comissioners and up to 576,54 € for
the physiotherapists across all groups. Lymphoedema treatment with 3M™ Coban
2™ compression system twice a week was more cost-effective than the other treat-
ments (ICER 37.65 € per % reduction of circumference vs. 146.60 € (daily), 145.67 €
(3x/wk) and 147.53 € (daily compression therapy with Comprilan® bandages)). Re-
sults were comparable for patients with CL of the upper and lower extremities,
respecitvely. Sensitivity analysis provided stable results after variation of costs,
utilization rates and clinical outcomes. CONCLUSIONS: Treatment of lymphoe-
dema with 3M™ Coban 2™ compression system twice a week is more efficient than
treatments applied daily or three times per week.
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OBJECTIVES: Transcatheter aortic valve implantation (TAVI) represents an inno-
vative technology superior to medical management (PARTNER study, US) in inop-
erable patients with severe aortic valve stenosis (AVS). This study aims to estimate
the cost-effectiveness of TAVI compared to conservative medical management in
symptomatic AVS patients in Spain. METHODS: A economic longitudinal cohort
model was used to predict clinical and economic outcomes of symptomatic AVS
patients treated with either transapical (TA) or transfemoral (TF) TAVI, or medical
management alone (MEDICAL). Clinical model input data for TAVI was derived
from the real-world SOURCE registry, and for MEDICAL from literature and a reg-
istry of 60 untreated Spanish AVS patients followed up for 336 days. Health utilities
as well as resource use and unit costs utilized for modelling are representative for
Spain. Missing information was substituted by expert estimates. Economic results
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are expressed as cost per quality adjusted life year (QALY) gained. Perspective is
that of the national health system (NHS). Benefits and costs were discounted with
3% per year. RESULTS: Over the 3 year analysis period, 2.12 life years per patient
were achieved with TA TAVI, 2.31 with TF TAVI and 1.51 with conservative medical
care, representing. 1.24, 1.38 and 0.74 QALYs, respectively. Cumulative direct costs
were predicted to amount to €37,311 and €35,689 with TA and TF TAVI, respectively
and to €23,103 with conservative care. Cost/QALY gained was €28,003 for TA TAVI
and €19,499 for TF TAVI, both ratios remaining well below the accepted willing-
ness-to-pay threshold for Spain. The substantial cost of the TAVI procedure was
largely offset over time mainly by savings related to prevented hospital readmis-
sions for cardiac reasons. Sensitivity analyses indicated these findings to be robust.
CONCLUSIONS: Compared to conservative management, TAVI is a life-saving and
cost-effective treatment for high-risk or inoperable patients with symptomatic
aortic valve stenosis in Spain.
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OBJECTIVES: The aim of this study was to combine clinical results from the RE-
VERSE study (Resynchronisation reverses Remodelling in Systolic Left Ventricular
Dysfunction) and costs associated with the addition of cardiac resynchronization
therapy (CRT) to optimal medical therapy (OMT) in patients with mild symptomatic
(NYHA I-II) or asymptomatic left ventricular dysfunction and markers of cardiac
dyssynchrony in Spain. METHODS: We developed a Markov model of CRT  OMT
(CRT-ON group) vs. OMT alone (CRT-OFF group) based on a retrospective cost-
effectiveness analysis. Raw data from the model was derived from literature and
expert opinion, reflecting clinical and economic consequences of patient’s man-
agement in Spain. Time horizon was 10 years, and costs were expressed in Euro
2010. Both costs and effects were discounted at 3% per annum. RESULTS: CRT-ON
group showed higher total costs than CRT-OFF, however patients with CRT reduced
94% the length of hospitalization in the ICU (0.006 vs. 0.091 days) and 34% in general
ward (0.705 vs. 1.076 days). Surviving patients with CRT-ON (88.2% vs. 77.5%) re-
mained in slighter functional class longer and they achieved an improvement of 0.9
life years (LYGs) and 0.77 years quality-adjusted life years (QALYs). In terms of cost
per LYGs, the results were €40,782 (5 years) and €18,431 (10 years), and in terms of
costs per QALYs gained were €39,800 and €21,500 at 5 and 10 years respectively.
Probabilistic sensitivity analysis showed that the probability of CRT-ON was cost-
effective is 65.54% at 10 years. CONCLUSIONS: The use of CRT added to OMT
represents an efficient use of resources in patients suffering from heart failure in
NYHA functional class I and II, with cost-effectiveness ratios below the Spanish
threshold at 10 years.
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OBJECTIVES: Case detection is key to identifying leprosy disease early in its devel-
opment for more effective prevention of progression to permanent disability. The
study evaluated the costs and cost-effectiveness of three leprosy case detection
methods in Nigeria’s north-eastern states of Adamawa and Gombe; namely Rapid
Village Survey (RVS), Household Contact Examination (HCE) and Traditional Heal-
er’s (THs) incentive approach METHODS: The study was cross-sectional and ex-
plorative, undertaken in routine practice setting, targeting endemic and non-en-
demic communities selected randomly. Primary and secondary data were collected
from routine practice records and the Nigerian Leprosy Elimination Programme
2009. All costs were measured from both providers’ and patients’ perspectives.
Effectiveness was measured as new cases detected and outcome expressed as cost
per case detected. Incremental approach, using routine passive case detection
method as a reference was used to estimate the costs and effects by comparing
each method against the routine practise; to measure additional cost per new case
detected, as incremental cost-effectiveness ratio (ICER). Univariate sensitivity
analysis was carried out to evaluate uncertainties around the ICER. All costs were
converted to US Dollars at the 2010 exchange rate. RESULTS:HCE generated a total
of $2416 at the lowest rate of $142 per additional case detected at all contact levels,
as the most cost-effective method while the RVS was dominated by THs method
which generated a total of $4447 at $193 per new case detected.Variation of diag-
nostic accuracy and subsistent wage for valuing unpaid time did not significantly
change the results. CONCLUSIONS: From both perspectives and at all contact lev-
els, the Household Contact Examination, complementing routine practice demon-
strated the most cost-effective approach to identifying new leprosy cases for effec-
tive prevention and control of leprosy in Nigeria. It will be necessary to carry out
implementation studies to establish the feasibility and acceptability of the method
in other leprosy areas.
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OBJECTIVES: To determine the cost-effectiveness of measuring glycated hemoglo-
bin with A1CNow ® compared with standard exam (SE) for DM2 patients, from the
Brazilian Private Healthcare System perspective. METHODS: The study was a cost-
effectiveness analysis based on Markov modeling to estimate costs and conse-
quences of treatments. Epidemiological and efficacy data derived from a critical
appraisal of the scientific literature. Only direct medical costs were considered. If
available, costs of clinical events (CE) were obtained from burden of disease stud-
ies. If not, Brazilian official guidelines were obtained to determine the resources
used to treat the CE. Drugs, hospital daily admission rates, procedures and labora-
tory tests unit costs were obtained from Brazilian official databases. Costs and
benefits were discounted at 5% yearly. Outcomes were expressed as CE avoided.
Probability sensitivity analysis (PSA) was conducted to assess model robustness.
Life time horizon was analyzed. RESULTS: Through the systematic review of the
literature the studies were selected to form the body of clinical data for the analy-
ses. The systematic review showed that although the absence of studies directly
evaluating the impact of A1CNow on cardiovascular events, their favorable influ-
ence on cardiovascular disease intermediate markers suggests that A1CNow may
have clinically relevant effect in patients at risk. The analysis showed higher clin-
ical benefits and lower costs for A1CNow. Considering 100 patients, 99.8 and 146.1
CE happen in A1CNow and SE arms, respectively. The average time-horizon cost
per patient was R$25,444(€11,108) and R$29,278(€12,782) for A1CNow and SE, re-
spectively, showing the dominance of A1CNow compared to SE. PSA demonstrated
that in 95.3% of the simulations A1CNow was dominant (more effective with lower
cost) compared to SE. CONCLUSIONS: Our study demonstrated that A1CNow have
clinically relevant effect in reducing CE being dominant for monitoring of glycated
hemoglobin in DM2 patients. PSA confirmed this determinist result.
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OBJECTIVES: Atrial Fibrillation (AF) is the most common arrhythmia among the
elderly. It has dire consequences, stroke being the most catastrophic. Its burden is
highly significant; changing demographics lead to more patients impacted. Man-
aging AF encompasses arrhythmia control and stroke prevention – with new tech-
nologies being developed for both. For Paroxysmal AF (PAF) – which terminates
spontaneously within 7 days – electrical Pulmonary Vein Isolation (PVI) has ad-
vanced as the cornerstone treatment in patients unresponsive to pharmaceuticals.
PAF accounts for 75% of patients, and half are medicated with sub-optimal out-
comes. We sought to evaluate the cost-effectiveness of PVI when using a new
balloon-based catheter using cooling energy for lesion creation (Arctic Front,
Medtronic). METHODS: A Markov Microsimulation Model compared treatment
with Arctic Front vs. conventional drugs. STOP-AF Pivotal Trial Data were used to
estimate PVI efficacy and complication rates. A literature review identified data for
long-term PVI and drug therapy outcomes. The model incorporated Arctic Front
specific complication rates (e.g. stroke, tamponade and phrenic nerve paralysis)
and drug toxicities and impact on stroke risk was included. Utility weights were
assigned for various health states. and a range of time horizons was used, with a UK
perspective adopted for costs and benefits. One-way and probabilistic sensitivity
analyses were undertaken. RESULTS: Depending on the time horizon, the ICER
ranged from £3,200/QALY to £15,700/QALY gained. Results were sensitive to as-
sumptions regarding long-term outcomes and the quality of life benefit of remain-
ing free of PAF. CONCLUSIONS: PVI can be highly cost-effective in treating PAF – a
highly prevalent and burdensome disease. Results are consistent with similar tech-
nology economic evaluations, and reinforce the evidence base for PVI as a cost-
effective therapy for PAF.
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OBJECTIVES: The main purpose of this study was to conduct an economic evalua-
tion of Primovist enhanced MRI (PV-MRI) compared to extracellular contrast-me-
dia-enhanced MRI (ECC-MRI) in patients suffering from liver metastases of colo-
rectal origin in Spain. METHODS: An analytic model previously implemented in
three European countries (Germany, Italy and Sweden) was adapted in Spain to
estimate all aggregated costs of both diagnosis options compared. Probabilities of
needing further imaging and of needing surgical plans modification or confirma-
tion were adjusted by Spanish clinical experts (surgeons and radiologists). Con-
trasts cost was estimated from PTR (weighting the different EECs prices for sales in
Spain for this option), and tests (MRI and CT) and different surgery procedures (high
or low risk, modification or confirmation of surgical plans, etc.) costs were ex-
tracted from official fees of different Spanish Autonomous Communities (CCAA).
RESULTS: PV-MRI was associated with a reduced need for extra imaging tests (6%
vs. 9%). Taking into account the costs of diagnosis tests and surgery procedures
(including modification of surgical plans during intervention), PV-MRI option was a
cost-neutral strategy, with total costs similar to ECC-MRI (576 € vs. € 578, PV-MRI vs
ECC-MRI respectively). CONCLUSIONS: Additional costs associated with colorectal
liver metastases diagnosis with PV-MRI regarding to ECC-MRI are offset by lower
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